Anhydrous alendronate monosodium salt formulations
US6008207A · kind A · utility
7Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 13, 1998 |
| Grant date | Dec 28, 1999 |
| Priority date | — |
| Expiry date | Aug 13, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/663
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical doage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.